Discovery and synthesis of novel substituted benzocoumarins as orally active lipid modulating agents

The synthesis of a series of benzocoumarin keto-enamine schiff bases is reported. The novel compounds were evaluated for their antihyperlipidemic activity in the hyperlipidemic hamster model. The compound 11 at a dose of 10 mg/kg body weight significantly lowered the plasma triglyceride levels (TG) by 70%, total cholesterol (TC) by 47%, accompanied by an increase in HDL-C/TC ratio by 80% in hyperlipidemic hamsters to a greater degree than the reference drugs atorvastatin and lovastatin.     

Antidyslipidemic activity of polyprenol from Coccinia grandis in high-fat diet-fed hamster model

Ethanol extract of Coccinia grandis (L.) Voigt showed significant triglyceride (TG) and cholesterol-lowering effects in dyslipidemic hamster model. Ethanolic extract was fractionated into chloroform, n-butanol and water-soluble fractions and were evaluated. Activity was proved to be concentrated in chloroform-soluble fraction. Chloroform-soluble fraction containing active component was subjected to repeated column chromatography, furnished a polyprenol characterized as C₆₀-polyprenol (1) isolated for the first time from this plant. It significantly decreased serum TG by 42%, total cholesterol (TC) 25% and glycerol (Gly) 12%, accompanied HDL-C/TC ratio 26% in high-fat diet (HFD)-fed dyslipidemic hamsters at the dose of 50 mg/kg body weight. Results are comparable to standard drug fenofibrate at the dose of 108 mg/kg. Based on these investigations, it was concluded that the compound polyprenol (1) isolated from leaves of C. grandis possess marked antidyslipidemic activity.     

Antidyslipidemic activity of furano-flavonoids isolated from Indigofera tinctoria

Flavonoids appear to play a major role in reducing the risk of cardiovascular diseases by decreasing the blood lipid levels. In continuation of our drug discovery program on antidyslipidemic agents we have isolated three furano-flavones 1-3 and a rare flavonol glycoside 4 from the aerial parts of Indigofera tinctoria. Our results disclose that the treatment with diastereomeric flavonoid mixture 1 and 2 (80:20) significantly decreased the plasma triglycerides (TG) by 60%, total cholesterol (TC) 19%, glycerol (Gly) 13%, and free fatty acid (FFA) 25% accompanied with increase in high density lipoproteins-cholesterol (HDL-C) by 8% and HDL-C/TC ratio 36% in high fat diet (HFD) fed dyslipidemic hamsters at the dose of 50 mg/kg body weight. The flavonoid 3 has exhibited moderate antidyslipidemic activity.     

葛根素对2型糖尿病大鼠的治疗作用*

目的:观察葛根素对2型糖尿病(T2DM)大鼠的治疗作用。方法:采用高糖高脂饲料喂养加一次性腹腔注射60 mg/kg链脲佐菌素的方法建立T2DM 大鼠模型,随机分为正常组,模型组,二甲双胍(40 mg/kg)组,葛根素低、中、高剂量(40,80,160 mg/kg)组,每组10只大鼠;造模成功后,灌胃给药4周,每周测量大鼠体重和空腹血糖(FBG),末次给药24 h后取血,收集血清,检测各组大鼠的血糖、血清甘油三酯(TG)、总胆固醇(TC) 、低密度脂蛋白-胆固醇(LDL-C)水平、高密度脂蛋白-胆固醇(HDL-C),血清天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)活性,血清尿素氮(BUN)、肌酐(SCr)、尿酸(UA)水平。结果:干预4周后,与正常组比较,模型组大鼠体重显著降低(P＜0.01),FBG,TC,TG,LDL-C,ALT,AST,BUN,SCr,UA均显著升高(P＜0.01),而HDL-C 显著降低(P＜0.01);与模型组比较,二甲双胍组和葛根素各剂量组大鼠体重均显著增加(P＜0.01),FBG,TC,TG,LDL-C,ALT,AST,BUN,SCr,UA均显著降低(P＜0.01),而HDL-C显著升高(P＜0.01)。结论:葛根素能够减少T2DM大鼠体重降低幅度,降低血脂、血糖水平,可用于T2DM的治疗。     

The Disappearance Rate in Reindeer of Famphur an Organophosphorus Parasiticide

The present investigations were carried out in order to study the disappearance rate in reindeer of famphur (0,O-dimethyl-O,p-(NtN-di-methylsulphamoyl) phenyl phosphorothioate), a promising systemic parasiticide for the control of reindeer warble and nostril flies. The compound was administered intramuscularly to reindeer as a single dose (in the form of the preparation Warbcx). At a dose of 20 mg/kg body weight (2 animals) famphur caused inhibition of plasma and erythrocyte cholinesterase activities by about 50 %. The plasma esterase activity fell off rapidly, within 24 hrs., and returned to normal within 3 weeks, whereas the erythrocyte esterase activity decreased gradually and remained low for at least 4 weeks after dosing. Peak plasma levels of fampliiir, varying between 1 and 16 p.p.m., were attained within 5–33 hrs., after a dose of 30 mg famphur per kg body weight (7 reindeer). The plasma levels declined to below 0.02 p.p.m. in 72–96 hrs. Famoxon, the oxygen analogue of famphur, was observed for 1–2 days in plasma at low levels, amounting to about 10 % of the corresponding famphur levels. In erythrocytes practically no residues were found of either compound. Tissue residue levels were low — except at the injection site. In a series of animals given a dose of 30 mg/kg body weight and killed at varying times after treatment famphur or famoxon were detectable in liver for 4.5 days and in kidney and skeletal muscle remote from the injection site for 12 days. In muscle tissue from the injection site highly variable residue levels were observed, indicating absorption from the intramuscular depot to be erratic. The experimental results suggest that no appreciable consumer hazard would arise from a proposed single-dose intramuscular treatment of reindeer with famphur at a dosage not exceeding 30 mg/kg body weight, provided a minimum interval of 3 weeks is maintained between treatment and slaughter and the muscle tissue around the injection site is discarded.     

Effect of a novel insulinotropic agent, succinic acid monoethyl ester, on lipids and lipoproteins levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes

In the present study, the effect of succinic acid monoethyl ester (EMS) on the pattern of lipids and lipoproteins in streptozotocin-nicotinamide induced type 2 diabetes was investigated. Type 2 diabetes was induced in male Wistar rats by single intraperitoneal injection (i.p.) of 45 mg/kg streptozotocin, 15 min after the i.p administration of 110 mg/kg body weight of nicotinamide. The carboxylic nutrient EMS was administered intraperitonially at a dose of 8 Μmol/g body weight for 30 days. At the end of experimental period, the effect of EMS on plasma glucose, insulin, thiobarbituric acid reactive substances (TBARS) and hydroperoxide (HP) and serum triglycerides (TG), phospholipids (PL), free fatty acids (FFA), total cholesterol (TC), very low density lipoprotein-cholesterol (VLDL-C) and low density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and the percentage of antiatherogenic index (AAI) (ratio of HDL-C to total cholesterol) were studied. Administration of EMS to diabetic rats resulted in a signi. cant reduction in the elevated levels of plasma glucose, TBARS and hydroperoxides as well as TG, PL, FFA, TC, VLDL-C and LDC-C levels. The decreased plasma insulin and serum HDL-C and percentage of AAI in diabetic rats were also reversed towards near normal. The effect produced by EMS was compared with metformin, a reference drug. The results indicates that the administration of EMS and metformin to nicotinamide-streptozotocin diabetic rats normalized plasma glucose, insulin concentrations and caused marked improvement in altered lipids, lipoprotein and lipid peroxidation markers during diabetes. Our results show the antihyperlipidemic properties of EMS and metformin in addition to its antidiabetic action. Moreover, the antihyperlipidemic effect could represent a protective mechanism against the development of atherosclerosis.     

Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity

In continuation of our drug discovery program on metabolic diseases, we identified an alkaloidal amide, that is, Aegeline (V) from the plant Aegle marmelos leaves as a dual acting agent (antihyperlipidemic and antihyperglycemic). We therefore synthesized a series of alkaloidal amides [N-(2-hydroxy-2-p-tolylethyl)-amides and N-(2-oxo-2-p-tolylethyl)-amide derivatives] related to Aegeline and screened for their in vivo antihyperlipidemic activity in Triton induced hyperlipidemia model. The synthetic compounds 4, 17 and 20 showed equipotent activity to the natural product, that is, Aegeline (V). These compounds also showed strong antioxidant activity, which support their antihyperlipidemic activity. Compound 12 showed better antihyperlipidemic and antioxidant profile than the natural product V.     

格列齐特对糖尿病大鼠心肌的保护作用及其机制*

目的: 观察格列齐特对糖尿病大鼠心肌保护作用及其可能的机制。方法: 将60只健康SD大鼠随机分为正常组(NC,n=10),造模组(n=50)给予高糖高脂饲料4周后,腹腔注射STZ(45 mg/kg)建立糖尿病大鼠模型,随机抽取以FBG≥16.7 mmol/L作为糖尿病模型建立成功。将造模成功的38只糖尿病大鼠随机分为模型组(MC,n=9)、格列齐特组(Glic,80 mg/kg,n=10)、格列本脲组(Glib,2.5 mg/kg,n=10)、法舒地尔组(Fas,10 mg/kg,n=9);NC组和MC组灌胃等容积蒸馏水,Glic组和Glib组灌胃给药,Fas组采用腹腔注射。各组大鼠每天给药一次,每周记录体质量及空腹血糖(FBG),持续8周。实验结束时取血并测定心脏质量,计算心脏质量指数(HWI);测定各组糖化血红蛋白(HbA1c)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)含量以及血清丙二醛(MDA)水平和超氧化物歧化酶(SOD)活性;通过HE和Masson染色,观察心肌病理变化和组织胶原纤维水平;TUNEL染色观察并计算心肌细胞凋亡率;Western blot法检测心肌组织中RhoA、ROCK1、eNOS、Bcl-2和Bax蛋白表达。结果: 与NC组比较,MC组FBG、HWI、HbA1c、TC、TG、LDL-C、MDA水平,心肌组织胶原沉积和心肌细胞凋亡率以及心肌组织中RhoA、ROCK1、Bax蛋白明显升高,SOD活性及HDL-C、eNOS、Bcl-2和体重显著降低(P＜0.01);与MC组相比,Glic组FBG、HWI、HbA1c、TC、TG、LDL-C和MDA等指标明显下降,心肌组织胶原沉积及心肌细胞凋亡减轻,心肌组织RhoA、ROCK1、Bax蛋白表达下调(P＜0.01或P＜0.05),大鼠体重和血清中SOD活性,HDL-C升高,eNOS、Bcl-2蛋白水平升高(P＜0.01或P＜0.05)。与Glic组相比,Glib组与Fas组体重、血脂、FBG、HWI、MDA以及心肌纤维化和心肌细胞凋亡水平升高,SOD和Bcl-2降低,Glib组心肌组织RhoA、ROCK1、Bax蛋白表达上调(P＜0.01或P＜0.05)。结论: 格列齐特可改善糖尿病大鼠心肌损伤并减轻心肌细胞凋亡水平,其机制可能与降低血糖,改善氧化应激状态,调控RhoA/ROCK1/eNOS信号通路有关。     

不同剂量阿伐他汀联合阿司匹林治疗原发性高血压并动脉粥样硬化的临床研究

目的:探讨不同剂量阿托伐他汀联合阿司匹林治疗原发性高血压并动脉粥样硬化的临床疗效。方法:选取2015年1月-2016年12月在我院治疗的原发性高血压并动脉粥样硬化患者80例,随机分为对照组和实验组,每组40例。实验组给予口服高剂量阿托伐他汀(40 mg/d)联合阿司匹林肠溶片(100 mg/d)治疗,对照组给予口服高剂量阿托伐他汀(20 mg/d)联合阿司匹林肠溶片(100 mg/d)治疗,疗程均为3个月。观察和比较两组患者治疗前后的总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high-density lipoproteincholesterol,HDL-C)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)、收缩压(systolic blood pressure,SBP)、舒张血压(diastolic blood pressure,DBP)以及颈动脉斑块分级。结果:两组治疗后的SBP、DBP、血清TC、TG和LDL-C水平均较治疗前显著降低,血清HDL-C水平较治疗前明显升高,且实验组SBP、DBP、血清TC、TG和LDL-C水平均显著低于对照组(P0.05),血清HDL-C水平明显高于对照组(P0.05)。实验组颈动脉斑块0-Ⅰ级的比例显著高于对照组(P0.05)。结论:口服高剂量阿托伐他汀(40 mg/d)联合阿司匹林肠溶片(100 mg/d)治疗原发性高血压并动脉粥样硬化较低剂量阿托伐他汀(20 mg/d)联合阿司匹林肠溶片(100 mg/d)疗效更好,可以有效降低血压,调节血脂并改善患者预后。     

Effects of fenofibrate on lipid parameters in obese rhesus monkeys

Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lowering triglycerides in experimentally-induced dyslipidemia in nonhuman primate models. The spontaneously obese rhesus monkey is a well-recognized animal model for the study of human obesity and type 2 diabetes, and many of these monkeys exhibit naturally occurring lipid abnormalities, including elevated triglycerides and low HDL cholesterol (HDL-C), similar to patients with type 2 diabetes. To explore whether the obese rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated fenofibrate in six hypertriglyceridemic, hyperinsulinemic, nondiabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. Fenofibrate (30 mg/kg b.i.d) decreased serum triglycerides 55% and LDL-C 27%, whereas HDL-C increased 35%. Apolipoproteins B-100 and C-III levels were also reduced 70% and 29%, respectively. Food intake, body weight, and plasma glucose were not affected throughout the study. Interestingly, plasma insulin levels decreased 40% during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity. These results support the use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C.     

虫草素对慢性肾脏病大鼠血管内皮损伤的保护作用及其机制

摘要 目的：探讨虫草素对慢性肾脏病(chronic kidney disease,CKD)大鼠血管内皮损伤的保护作用及其机制。方法：慢性肾脏病大鼠(n=48)随机平分为四组-模型组、虫草素高剂量组、虫草素中剂量组、虫草素低剂量组,虫草素高剂量组、虫草素中剂量组、虫草素低剂量组,分别给予虫草素160 mg/kg、80 mg/kg、40 mg/kg,模型组灌胃给予等量生理盐水,每天1次,连续给药治疗2周。结果：虫草素高剂量组、虫草素中剂量组、虫草素低剂量组治疗1周、治疗2周的24 h尿量、血清尿素氮(blood urea nitrogen,BUN)与肌酐(serum creatinine,Scr)水平都低于模型组(P<0.05),体重都高于模型组(P<0.05),不同剂量组别之间对比差异也有统计学意义(P<0.05)。虫草素高剂量组、虫草素中剂量组、虫草素低剂量组治疗2周的结缔组织生长因子(Connective tissue growth factor,CTGF)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)蛋白相对表达水平高于模型组(P<0.05),肾小球硬化指数、肾小管损伤评分都低于模型组(P<0.05),不同剂量组别之间对比差异也有统计学意义(P<0.05)。结论：虫草素在慢性肾脏病大鼠的应用能发挥血管内皮损伤保护作用,促进改善大鼠的肾功能,提高大鼠的体重,且具有剂量依赖性。     

瘦素对糖尿病大鼠糖脂代谢及炎性因子的影响

目的: 探讨瘦素对糖尿病大鼠糖脂代谢及相关炎症因子的影响。方法: 将健康Wistar雄性大鼠60只随机选取10只作为对照组,50只给予高糖高脂饲料喂养加腹腔内注射链脲佐霉素(STZ,25 mg/kg)的方法诱发并建立糖尿病大鼠模型。并随机分为模型组、瘦素低剂量组、瘦素中剂量组和瘦素高剂量组,每组10只。4组大鼠造模成功后均持续给予高糖高脂饲料喂养,瘦素低、中、高剂量组给予20 μg/kg、50 μg/kg和100 μg/kg,连续5 d。GOD-PAP法检测大鼠血糖(FBG),放射免疫法测定胰岛素含量(Ins),全自动生化分析仪测定血清中三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)。采用酶联免疫方法(ELISA)测定丙二醛(MDA)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)。采用Western blot检测糖尿病大鼠脂肪组织中瘦素表达情况。结果: 与对照组比较,各组大鼠血糖水平均显著升高(P＜0.01);与模型组比较,瘦素中、高剂量大鼠血糖显著降低(P＜0.05,P＜0.01);瘦素高剂量组胰岛素水平显著降低(P＜0.01)。不同剂量瘦素组间比较,给药后三组大鼠FBG及INS无统计学差异(P＞0.05)。与模型组比较,瘦素中、高剂量组TC水平显著下降(P＜0.05,P＜0.01);高剂量组TG、LDL-C水平显著降低(P＜0.05),高剂量组HDL-C水平显著升高(P＜0.01)。不同剂量瘦素组进行组间比较,高剂量组在降低TC、TG、LDL-C水平,升高HDL-C水平优于中、低剂量组(P＜0.05)。Western blot结果显示,与模型组(52.27±10.93)比,瘦素高剂量组100 μg/kg(40.13±9.87)、中剂量组50 μg/kg(44.68±10.23)、低剂量组20 μg/kg(47.35±12.09)脂肪中瘦素表达水平依次降低。结论: 瘦素水平分泌异常是诱发糖尿病因素之一,在给予一定浓度外源性瘦素(100 μg/kg)干预下,能显著降低MDA、TNF-α水平,提高IL-6水平,其机制可能与瘦素在减轻炎症反应、氧化应激,纠正血脂异常紊乱有密切关系。     

Effect of oral nitroethane and 2-nitropropanol administration on methane-producing activity and volatile fatty acid production in the ovine rumen

Strategies are sought to reduce economic and environmental costs associated with ruminant methane emissions. The effect of oral nitroethane or 2-nitropropanol administration on ruminal methane-producing activity and volatile fatty acid production was evaluated in mature ewes. Daily administration of 24 and 72 mg nitroethane/kg body weight reduced (P<0.05) methane-producing activity by as much as 45% and 69% respectively, when compared to control animals given no nitroethane. A daily dose of 120 mg 2-nitropropanol/kg body weight was needed to reduce (P<0.05) methane-producing activity by 37% from that of untreated control animals. Reductions in methane-producing activity may have been diminished by the last day (day 5) of treatment, presumably due to ruminal adaptation. Oral administration of nitroethane or 2-nitropropanol had little or no effect on accumulations or molar proportions of volatile fatty acids in ruminal contents collected from the sheep. These results demonstrate that nitroethane was superior to 2-nitropropanol as a methane inhibitor and that both nitrocompounds reduced ruminal methanogenesis in vivo without redirecting the flow of reductant generated during fermentation to propionate and butyrate.     

Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats

The teratogenicity of trans-2-ene-valproic acid (300 and 400 mg/kg) was compared with that of valproic acid (VPA; 300 mg/kg) and controls (corn oil) administered by gavage to Sprague-Dawley CD rats on embryonic (E) days 7-18. At the 300 mg/kg dose, trans-2-ene-VPA produced no change in maternal weight, number of implantations, proportion of resorptions, proportion of malformations, or fetal weight. By contrast, the same dose of VPA (300 mg/kg) reduced maternal weight during gestation, increased malformations (12.0% vs. 0.7% in controls), and reduced fetal body weight by 25.1%. An even higher dose of trans-2-ene-VPA (400 mg/kg) produced a reduction in maternal body weight during treatment and reduced fetal body weight (by 7.9%), but did not increase resorptions or malformations in the fetuses. On day E18, maternal serum drug concentrations of VPA were higher in the VPA-treated group compared with those of trans-2-ene-VPA in the trans-2-ene-VPA-treated groups at 1 hr posttreatment. At 6 hr posttreatment the reverse was seen. trans-2-ene-VPA may be absorbed more rapidly and distributed differently than VPA. Overall, the data support the view that trans-2-ene-VPA at equal or higher doses than VPA is not teratogenic in rats.     

Effects of Se-enriched polysaccharides produced by Enterobacter cloacae Z0206 on alloxan-induced diabetic mice

In this study, the water-soluble selenium-enriched exopolysaccharides (Se-ECZ-EPS) were isolated from submerged culture broth of Enterobacter cloacae Z0206 through fermentation, ethanol precipitation and deproteinization. The protective effects of Se-ECZ-EPS on alloxan-induced diabetic mice were investigated. Diabetes was induced in ICR (Institute of Cancer Research) mice by administration of single doses of alloxan intraperitoneally (190 mg/kg body weight). Se-ECZ-EPS at a dose of 200 mg/kg body weight were administered per os (p.o.) as single dose per day to diabetes-induced mice for a period of 42 days. The decrease in body weight, serum insulin level, and the increase in blood glucose level, glycosylated serum protein (GSP), total cholesterol (TC) and triglycerides (TG) in liver were observed in diabetic mice. On the other hand, oral administration of Se-ECZ-EPS resulted in a significant reduction in fasting blood glucose levels, GSP, TC and TG contents in liver coupled with improvement of body weight and serum insulin level in comparison with diabetic control group. These results suggest that Se-ECZ-EPS possess significant protective and anti-diabetic effects in alloxan-induced diabetic mice.     

In vivo radioprotection by alpha-TMG: preliminary studies

alpha-TMG is a novel water-soluble derivative of Vitamin E that has shown excellent antioxidant activity. The parent compound has demonstrated protection against radiation induced chromosomal damage in vivo. Hence, the preliminary experiments to determine the radioprotective activity of alpha-TMG were carried out in adult Swiss albino mice. Acute toxicity of the drug was studied taking 24h, 72 h and 30 day mortality after a single intraperitoneal injection of 500-2000 mg/kg body weight of the drug. The drug LD(50) for 24h and 72 h/30 day survival were found to be 1120 and 1000 mg/kg body weight, respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 600 mg/kg of the drug 15 min before or within 5, 15 or 30min after 3Gy whole body gamma radiation resulted in a significant decrease in the aberrant metaphases percent at 24h post-irradiation; the maximum effect was seen when the drug was given immediately after irradiation. Injection of 200-800 mg/kg TMG within 5 min of irradiation with 3 Gy produced a significant dose-dependent reduction in the radiation induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 600 mg/kg body weight. At this dose, TMG produced 70 and >60% reduction in the radiation induced percent aberrant metaphases and micronucleated erythrocytes, respectively. The high water solubility and effectiveness when administered post-irradiation favor TMG as a likely candidate for protection in case of accidental exposures.     

五指山小型猪高脂血症模型的心脏自主神经功能变化

目的观察五指山小型猪高脂血症模型的心脏自主神经功能的动态变化,探讨血脂异常对自主神经功能的影响和与昼夜的关系。方法利用高脂饮食诱发五指山小型猪高脂血症,造模后,每2周一次测定小型猪TG、TC、HDL-C和LDL-C和监测动态心电图,并进行24 h和昼夜心率变异性（HRV）分析,以评估小型猪的心脏自主神经功能。结果高脂饮食2周后五指山小型猪血清TC、HDL-C、LDL-C水平均显著升高（P〈0.01）,TG水平亦在高脂饮食后6周显著升高（P〈0.05）,其中,TC、LDL-C在高脂饮食0～4周时呈快速上升,在4～6周达到高峰,8～10周基本稳定并维持在一定水平;HDL-C在高脂饮食0～2周迅速上升并达到高峰,2～10周基本稳定。HRV参数分析结果,时域指标（RRI、SDNN、RMSDD、SDANN、PNN50、SDANN index、STV、LTV）和频域指标（VLF、LF、HF和TP）均渐进性显著降低（P〈0.05,P〈0.01）,LF/HF升高（P〈0.05）,夜间HRV参数变化程度均高于白天;相关分析显示HRV各参数与TC、LDL-C、TC/HDL-C、LDL-C/HDL-C具有显著的相关性（P〈0.05,P〈0.01）,经多元线性逐步回归分析发现,SDNN与TC、LDL-C、TC/HDL-C、LDL-C/HDL-C比值的相关性依次为0.673、0.672、0.665、0.681。结论高脂饮食诱发五指山小型猪高脂血症的血脂异常可引起自主神经功能的下降和紊乱,自主神经功能的紊乱程度与高血脂状态的持续时间有关;血脂异常所致心血管疾病的危险程度夜间高于白天;HRV降低与TC、LDL-C、TC/HDL-C和LDL-C/HDL-C比值升高呈一定的依赖性,SDNN降低可作为预测高脂血症引发心血管病风险的独立相关指标。     

Effect of testosterone on carboxypeptidase H activity in the murine hypothalamus and hypophysis

Effects of single intraperitoneal administration of testosterone propionate (3 or 30 mg/kg body weight) on activity of carboxypeptidase H in pituitary body and hypothalamus of female white mouse were studied. It was found that testosterone propionate treatment (3 and 30 mg/kg body weight) increased the carboxypeptidase H activity in pituitary through 0.5 hour and it decreased one in 24 hours after treatment. The carboxypeptidase H activity in hypothalamus was lower as compared with control animals in 24 hours after testosterone propionate treatment in the dose 3 mg/kg body weight. However, the carboxypeptidase H activity in hypothalamus was lower in 0.5 and 24 hours and it was higher in 4 h after testosterone propionate treatment in the dose 30 mg/kg body weight as compared with the control. These data suggest that testosterone affects the carboxypeptidase H activity by changing the level of enzyme gene expression.     

阿霉素注射剂量对肾病综合征大鼠脂蛋白脂酶和卵磷脂胆固醇酰基转移酶水平的影响

摘要 目的：探讨阿霉素注射剂量对肾病综合征（nehpmtic syndrome,NS）大鼠脂蛋白脂酶和卵磷脂胆固醇酰基转移酶（Leci-thin cholesterol acyltransferase,LCAT）水平的影响。方法：64只SD大鼠随机平分为四组-对照组、小剂量阿霉素组、中剂量阿霉素组与高剂量阿霉素组,四组大鼠经尾静脉一次性注射阿霉素0 mg/kg、2 mg/kg、4 mg/kg、8 mg/kg,检测造模后不同时间点大鼠肾脏脂蛋白脂酶和卵磷脂胆固醇酰基转移酶水平变化情况。结果：小剂量阿霉素组、中剂量阿霉素组与高剂量阿霉素组造模后7 d、14 d、21 d的体重与每日采食量、血肌酐与尿素氮都低于对照组（P<0.05）,24 h尿蛋白高于对照组（P<0.05）,且存在剂量依赖性,三组间对比差异有统计学意义（P<0.05）。小剂量阿霉素组、中剂量阿霉素组与高剂量阿霉素组造模后21 d、28 d的肾脏脂蛋白脂酶和卵磷脂胆固醇酰基转移酶相对表达水平低于对照组（P<0.05）,且存在剂量依赖性,三组间对比差异有统计学意义（P<0.05）。结论：小剂量阿霉素可抑制大鼠肾脏脂蛋白脂酶和卵磷脂胆固醇酰基转移酶的表达,能快速有效建立肾病综合征大鼠模型,具有很好的模拟造模效果。     

乙酰辅酶A羧化酶抑制剂联合非诺贝特对小鼠非酒精性脂肪肝的治疗效果

摘要 目的：探讨乙酰辅酶A羧化酶抑制剂（MK-4074）联合非诺贝特对小鼠非酒精性脂肪肝（NAFLD）的脂质含量以及肝功能的改善效果。方法：20只C57BL/6小鼠给予60%高脂饲料连续喂养8周构建NAFLD小鼠模型后，随机分为安慰剂组、MK-4074组、非诺贝特组以及MK-4074联合非诺贝特治疗组，每组各5只，继续高脂喂养并分别给予安慰剂（Placebo）、MK-4074（10 mg/kg/天）、非诺贝特（30 mg/kg/天）、以及MK-4074（10 mg/kg/天）+ 非诺贝特（30 mg/kg/天）治疗持续8周。治疗结束后对小鼠体重、肝指数、肝脏脂质含量、肝功能以及肝脏病理和肝脏中性粒细胞和巨噬细胞浸润情况进行分析。结果：与安慰剂组相比，单用MK-4074治疗可显著降低肝指数、肝脏甘油三酯（TG）、胆固醇（TC）、非酯化脂肪酸（NEFA）的含量以及血清ALT和AST水平，而对小鼠体重和血清TC没有显著影响；单用非诺贝特可显著降低小鼠体重，肝脏TG、TC、NEFA以及血清TG、 ALT和AST水平，对小鼠的肝指数、血清TC没有显著影响；而MK-4074与非诺贝特联合治疗可显著降低小鼠体重、肝脏TG、TC、NEFA，以及血清TG、ALT和AST水平，降低肝脏脂质积累以及中性粒细胞与巨噬细胞浸润，效果优于MK-4074或非诺贝特单药治疗。结论：MK-4074联合非诺贝特可显著减少NAFLD小鼠肝脏的脂质含量，改善肝功能。